Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vitelline membrane outer layer 1 homolog (VMO1)
- Target
- VMO1
- Molecular classification
- Other (secreted structural and functional protein; not a receptor, enzyme, transporter, or transcription factor)
01
Overview
Vitelline membrane outer layer 1 homolog (VMO1) is a secreted protein originally characterized in the outer layer of avian egg vitelline membranes, where it binds tightly to ovomucin fibrils and contributes to the membrane's structure and antimicrobial function[1][3]. In mammals, such as humans, VMO1 is a 21 kDa secreted protein not linked to cytokine receptor function; it is subject to a rare post-translational modification called *C*-mannosylation, which affects its intracellular stability (destabilizing when mannosylated at a specific tryptophan residue), but does not appear to regulate secretion[3]. In humans, VMO1 has been found to interact with lysozyme C in tear film and may have extracellular structural or protective roles[3]. There are no known drugs, clinical biomarker applications, or notable safety concerns associated with the protein, and it is not classified as a therapeutic target.
- Other names
- Vitelline membrane outer layer protein 1 (VMO-I)VMO1Vitelline membrane outer layer 1 homolog (chicken)LOC327956 (mouse homolog)
02
Mechanism of action
Not applicable (no known drugs target VMO1 directly)
03
Biological functions
Contributes to the structure and antimicrobial barrier function of the vitelline membrane in eggs, binding to other matrix proteins such as ovomucinProtein stability modulation: subject to *C*-mannosylation, which affects its intracellular stabilityIn some species (e.g., chicken), exhibits antibacterial activity in the egg amniotic fluidIn humans, may play a role in tear film stability via interaction with lysozyme C
04
Disease associations
In chickens, highly expressed in some ovarian carcinomas, suggesting a potential biomarker role in ovarian cancer in hensHuman VMO1 observed as present in urine samples of some cancer patients (esophagogastric junctional cancers), but disease relevance remains unclear
05
Biomarkers
In chickens, VMO1 may be a biomarker of ovarian carcinomaNo established clinical biomarker use in humans
Beyond the preview
Go deeper on Vitelline membrane outer layer 1 homolog (VMO1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vitelline membrane outer layer 1 homolog (VMO1).